Houlihan Financial Resource Group’s Bicycle Therapeutics BCYC Stock Holding History

Houlihan Financial Resource Group’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$4K	Buy	+223	New	+$3.94K	﹤0.01%	301

Other funds holding BCYC

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Houlihan Financial Resource Group's BCYC Position: Q3 2020 in Review

Houlihan Financial Resource Group opened a new position in Bicycle Therapeutics (BCYC) in Q3 2020: 223 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #301 among its holdings.

18 funds tracked by Wall St. Rank hold BCYC as of Q3 2020.

Houlihan Financial Resource Group held 223 shares of Bicycle Therapeutics worth $4K as of Q3 2020.
Bicycle Therapeutics was a new Houlihan Financial Resource Group position in Q3 2020.
Bicycle Therapeutics made up ﹤0.01% of Houlihan Financial Resource Group's portfolio in Q3 2020, its #301 holding.
18 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2020.

Based on Houlihan Financial Resource Group's 13F filing for Q3 2020, filed 13 Nov 2020.